| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
,
,¶
* Institute of Molecular Medicine for the Prevention of Human Diseases, University of Texas-Houston,
Department of Biochemistry and Molecular Biology, University of Texas-Houston Medical School, and Departments of
Medicine and
Immunology and
¶ Biology of Inflammation Center, Baylor University College of Medicine, Houston, TX 77030
Asthma is a chronic inflammatory disease of the lung resulting in airway obstruction. The airway inflammation of asthma is strongly linked to Th2 lymphocytes and their cytokines, particularly IL-4, IL-5, and IL-13, which regulate airway hyperresponsiveness, eosinophil activation, mucus production, and IgE secretion. Historically, complement was not thought to contribute to the pathogenesis of asthma. However, our previous reports have demonstrated that complement contributes to bronchial hyperreactivity, recruitment of airway eosinophils, IL-4 production, and IgE responses in a mouse model of pulmonary allergy. To define the complement activation fragments that mediate these effects, we assessed the role of the complement anaphylatoxin C3a in a mouse model of pulmonary allergy by challenging C3aR-deficient mice intranasally with a mixed Ag preparation of Aspergillus fumigatus cell culture filtrate and OVA. Analysis by plethysmography after challenge revealed an attenuation in airway hyperresponsiveness in C3aR-deficient mice relative to wild-type mice. C3aR-deficient mice also had an 88% decrease in airway eosinophils and a 59% reduction in lung IL-4-producing cells. Consistent with the reduced numbers of IL-4-producing cells, C3aR-deficient mice had diminished bronchoalveolar lavage levels of the Th2 cytokines, IL-5 and IL-13. C3aR knockout mice also exhibited decreases in IgE titers as well as reduced mucus production. Collectively, these data highlight the importance of complement activation, the C3a anaphylatoxin, and its receptor during Th2 development in this experimental model and implicate these molecules as possible therapeutic targets in diseases such as asthma.
This article has been cited by other articles:
|
|
 |
|
  X. Zhang, I. P. Lewkowich, G. Kohl, J. R. Clark, M. Wills-Karp, and J. Kohl A Protective Role for C5a in the Development of Allergic Asthma Associated with Altered Levels of B7-H1 and B7-DC on Plasmacytoid Dendritic Cells J. Immunol., April 15, 2009; 182(8): 5123 - 5130. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. G. Therien, V. Bernier, S. Weicker, P. Tawa, J.-P. Falgueyret, M.-C. Mathieu, J. Honsberger, V. Pomerleau, A. Robichaud, R. Stocco, et al. Adenovirus IL-13-Induced Airway Disease in Mice: A Corticosteroid-Resistant Model of Severe Asthma Am. J. Respir. Cell Mol. Biol., July 1, 2008; 39(1): 26 - 35. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Basham, M. Sathe, J. Grein, T. McClanahan, A. D'Andrea, E. Lees, and A. Rascle In vivo identification of novel STAT5 target genes Nucleic Acids Res., June 1, 2008; 36(11): 3802 - 3818. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Wills-Karp Complement Activation Pathways: A Bridge between Innate and Adaptive Immune Responses in Asthma Proceedings of the ATS, July 1, 2007; 4(3): 247 - 251. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Dillard, R. A. Wetsel, and S. M. Drouin Complement C3a Regulates Muc5ac Expression by Airway Clara Cells Independently of Th2 Responses Am. J. Respir. Crit. Care Med., June 15, 2007; 175(12): 1250 - 1258. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. A. Melendi, S. J. Hoffman, R. A. Karron, P. M. Irusta, F. R. Laham, A. Humbles, B. Schofield, C.-H. Pan, R. Rabold, B. Thumar, et al. C5 Modulates Airway Hyperreactivity and Pulmonary Eosinophilia during Enhanced Respiratory Syncytial Virus Disease by Decreasing C3a Receptor Expression J. Virol., January 15, 2007; 81(2): 991 - 999. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. L. Mueller-Ortiz, T. J. Hollmann, D. L. Haviland, and R. A. Wetsel Ablation of the complement C3a anaphylatoxin receptor causes enhanced killing of Pseudomonas aeruginosa in a mouse model of pneumonia Am J Physiol Lung Cell Mol Physiol, August 1, 2006; 291(2): L157 - L165. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Taube, J. M. Thurman, K. Takeda, A. Joetham, N. Miyahara, M. C. Carroll, A. Dakhama, P. C. Giclas, V. M. Holers, and E. W. Gelfand Factor B of the alternative complement pathway regulates development of airway hyperresponsiveness and inflammation PNAS, May 23, 2006; 103(21): 8084 - 8089. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. M. Drouin, M. Sinha, G. Sfyroera, J. D. Lambris, and R. A. Wetsel A Protective Role for the Fifth Complement Component (C5) in Allergic Airway Disease Am. J. Respir. Crit. Care Med., April 15, 2006; 173(8): 852 - 857. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Zhou, H. Patel, K. Li, Q. Peng, M.-B. Villiers, and S. H. Sacks Macrophages from C3-deficient mice have impaired potency to stimulate alloreactive T cells Blood, March 15, 2006; 107(6): 2461 - 2469. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Schaefer, S. Konrad, J. Thalmann, C. Rheinheimer, K. Johswich, B. Sohns, and A. Klos The Transcription Factors AP-1 and Ets Are Regulators of C3a Receptor Expression J. Biol. Chem., December 23, 2005; 280(51): 42113 - 42123. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. P. Gerard, B. Lu, P. Liu, S. Craig, Y. Fujiwara, S. Okinaga, and C. Gerard An Anti-inflammatory Function for the Complement Anaphylatoxin C5a-binding Protein, C5L2 J. Biol. Chem., December 2, 2005; 280(48): 39677 - 39680. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Honczarenko, M. Z. Ratajczak, A. Nicholson-Weller, and L. E. Silberstein Complement C3a Enhances CXCL12 (SDF-1)-Mediated Chemotaxis of Bone Marrow Hematopoietic Cells Independently of C3a Receptor J. Immunol., September 15, 2005; 175(6): 3698 - 3706. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. B. Martin and B. K. Martin Characterization of the Murine C3a Receptor Enhancer-Promoter: Expression Control by an Activator Protein 1 Sequence and an Ets-Like Site J. Immunol., September 1, 2005; 175(5): 3123 - 3132. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. G. Therien, R. Baelder, and J. Kohl Agonist Activity of the Small Molecule C3aR Ligand SB 290157 J. Immunol., June 15, 2005; 174(12): 7479 - 7480. [Full Text] [PDF]
|
|
|
|
|
|
R. Baelder, B. Fuchs, W. Bautsch, J. Zwirner, J. Kohl, H. G Hoymann, T. Glaab, V. Erpenbeck, N. Krug, and A. Braun Pharmacological Targeting of Anaphylatoxin Receptors during the Effector Phase of Allergic Asthma Suppresses Airway Hyperresponsiveness and Airway Inflammation J. Immunol., January 15, 2005; 174(2): 783 - 789. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Boos, I. L. Campbell, R. Ames, R. A. Wetsel, and S. R. Barnum Deletion of the Complement Anaphylatoxin C3a Receptor Attenuates, Whereas Ectopic Expression of C3a in the Brain Exacerbates, Experimental Autoimmune Encephalomyelitis J. Immunol., October 1, 2004; 173(7): 4708 - 4714. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Ahamed, R. T. Venkatesha, E. B. Thangam, and H. Ali C3a Enhances Nerve Growth Factor-Induced NFAT Activation and Chemokine Production in a Human Mast Cell Line, HMC-1 J. Immunol., June 1, 2004; 172(11): 6961 - 6968. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. M. Hogaboam, K. Takahashi, R. A. B. Ezekowitz, S. L. Kunkel, and J. M. Schuh Mannose-binding lectin deficiency alters the development of fungal asthma: effects on airway response, inflammation, and cytokine profile J. Leukoc. Biol., May 1, 2004; 75(5): 805 - 814. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Taube, Y.-H. Rha, K. Takeda, J.-W. Park, A. Joetham, A. Balhorn, A. Dakhama, P. C. Giclas, V. M. Holers, and E. W. Gelfand Inhibition of Complement Activation Decreases Airway Inflammation and Hyperresponsiveness Am. J. Respir. Crit. Care Med., December 1, 2003; 168(11): 1333 - 1341. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
